Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Up 827.2% in May

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 112,008 shares, an increase of 827.2% from the April 30th total of 12,080 shares. Based on an average daily volume of 927 shares, the short-interest ratio is currently 120.8 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Hansa Biopharma AB (publ) in a research note on Thursday, February 12th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Hansa Biopharma AB (publ) currently has a consensus rating of “Buy”.

Hansa Biopharma AB (publ) Stock Performance

Shares of HNSBF stock remained flat at $2.90 during mid-day trading on Friday. The stock has a 50-day moving average price of $2.90 and a two-hundred day moving average price of $2.91. Hansa Biopharma AB has a 1-year low of $2.90 and a 1-year high of $2.90.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.